Research
Hormonal
More patients in the tirzepatide group achieved a 1-stage or greater fibrosis improvement without worsening of MASH compared to placebo.
Tirzepatide may help improve liver fibrosis in patients with MASH.
StrongSupportsmedium confidence
Additionally, more patients in the tirzepatide group in comparison to placebo achieved a 1-stage or greater fibrosis improvement without worsening of MASH.
Why this rating
Based on results from a phase 2 clinical trial.
Source
Tirzepatide for metabolic dysfunction-associated steatohepatitis: results from phase II clinical trials and perspectives
Stefano Fiorucci et al. · Expert Opinion on Investigational Drugs · 2025
rctCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →